Introducing Rational Combinations of RAF/MEK Clamp Avutometinib: Breakthrough Designation & Beyond
Time: 2:45 pm
day: Day Two Track B PM
Details:
- Presenting RAF/MEK clamp Avutometinib and FAK inhibitor Defactinib which are in clinical development in RAS/MAPK driven cancers, offering new hope for patients
- Demonstrating the potential for improved patient outcomes with registration-directed trial design and clinical development progress in low-grade serous ovarian cancer (LGSOC) and other RAS/ MAPK driven cancers
- Discussing future directions, including clinical trials in new indications and combination treatment approaches to advance cancer treatment and benefit patients
